Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 –WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc.

Enerzair (formerly QVM149) consists of long-acting beta agonist (LABA) indacaterol, long-acting muscarinic antagonist (LAMA) glycopyrronium, and inhaled corticosteroid (ICS) mometasone furoate ...

randomized 2:1 to either LYR-210 (7500µg mometasone furoate) or sham control for 24 weeks. Planned Reverse Stock Split Lyra intends to implement a reverse stock split in order to increase the per ...

Eosinophilic esophagitis (EoE) is a multifaceted disease marked by diverse clinical features, including variations in age of onset, symptom ...

The dynamics of the eosinophilic esophagitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as APT-1011 (Ellodi Pharmaceuticals) ...

MSD Animal Health, a division of Merck & Co, Inc, announced that it has received FDA approval for its gentamicin, posaconazole, and mometasone furoate otic suspension (Mometamax Single; Merck). This ...

Each ENLIGHTEN trial enrolled approximately 180 CRS patients who have failed medical management and have not had prior ethmoid sinus surgery, randomized 2:1 to either LYR-210 (7500µg mometasone ...

At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...

Topical moisturizers Emollients (glycol and glyceryl stearate, soy sterols) — crm, oint, gel, lotion, oil Liberal and frequent reapplication. Apply soon after bathing to improve skin hydration ...

The strengths are as follows: One strip contains 50 micrograms (mcg), 100 mcg, or 200 mcg of fluticasone furoate per blister. The other strip contains 25 mcg of vilanterol per blister. A blister ...